American biotechnology firms want U.S. trade negotiators to stress the need for a more flexible import process of genetically modified products as trade talks with the European Union pick up speed.
How to deal with genetically modified imports is the most contentious issue facing trade agreement negotiations between the U.S. and European Union this summer. “We need a trade agreement that is flexible and can accommodate technology,” said Matt O’Mara, director of foreign affairs for the Biotechnology Industry Organization. “We need technology. There is no more land. We need to use existing resources in a much more efficient way.”
Read the full, original post here: American biotech pushes for fewer Europe barriers
